Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China · Delayed Price · Currency is CNY 46.09
+0.22 (0.48%)
May 8, 2026, 3:04 PM CST
SHE:300255 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 855.6 | 858.2 | 997.77 | 1,397 | 2,327 | 2,941 |
Other Revenue | 16.93 | 16.93 | 33.04 | 13.25 | 9.65 | 27.3 |
| 872.53 | 875.13 | 1,031 | 1,410 | 2,336 | 2,968 | |
Revenue Growth (YoY) | -12.32% | -15.10% | -26.92% | -39.63% | -21.29% | 25.56% |
Cost of Revenue | 848.43 | 854.27 | 937.35 | 1,733 | 1,315 | 1,246 |
Gross Profit | 24.1 | 20.86 | 93.46 | -322.77 | 1,021 | 1,722 |
Selling, General & Admin | 185.18 | 183.87 | 216.34 | 630.71 | 739.69 | 1,220 |
Research & Development | 31.11 | 34.08 | 47.19 | 158.82 | 145.01 | 150.63 |
Other Operating Expenses | 9.72 | 9.46 | 2.11 | 17.24 | 22.02 | 26.77 |
Operating Expenses | 259.31 | 256.94 | 272.24 | 822.15 | 913.23 | 1,398 |
Operating Income | -235.21 | -236.07 | -178.78 | -1,145 | 107.99 | 324.06 |
Interest Expense | -97.4 | -96.91 | -102.83 | -96.41 | -93.04 | -62.29 |
Interest & Investment Income | 3.34 | 3.6 | 37.02 | 1.85 | 1.99 | 1.3 |
Currency Exchange Gain (Loss) | 5.24 | 5.24 | 0.25 | 4.76 | 6.69 | -4.4 |
Other Non Operating Income (Expenses) | -31.15 | -27.26 | -15.36 | -13.67 | -12.8 | -10.13 |
EBT Excluding Unusual Items | -355.19 | -351.39 | -259.7 | -1,248 | 10.84 | 248.54 |
Impairment of Goodwill | - | - | - | -1.78 | -1.78 | - |
Gain (Loss) on Sale of Assets | -0.23 | -0.23 | -0.78 | -0 | -0.09 | -0.11 |
Asset Writedown | -3.68 | -3.68 | -1.3 | - | -0.27 | - |
Other Unusual Items | 4.97 | -0.59 | 4.7 | 18.49 | 9.41 | 11.98 |
Pretax Income | -354.12 | -355.89 | -257.08 | -1,232 | 18.12 | 260.41 |
Income Tax Expense | 11.58 | 11.57 | 6.95 | 16.46 | 7.96 | 29.15 |
Earnings From Continuing Operations | -365.71 | -367.46 | -264.03 | -1,248 | 10.16 | 231.26 |
Minority Interest in Earnings | 9.9 | 9.57 | 14.55 | 7.94 | 7.36 | 2.31 |
Net Income | -355.81 | -357.9 | -249.48 | -1,240 | 17.51 | 233.57 |
Net Income to Common | -355.81 | -357.9 | -249.48 | -1,240 | 17.51 | 233.57 |
Net Income Growth | - | - | - | - | -92.50% | -7.62% |
Shares Outstanding (Basic) | 916 | 918 | 924 | 919 | 876 | 934 |
Shares Outstanding (Diluted) | 916 | 918 | 924 | 919 | 876 | 934 |
Shares Change (YoY) | -0.92% | -0.68% | 0.58% | 4.91% | -6.27% | -0.23% |
EPS (Basic) | -0.39 | -0.39 | -0.27 | -1.35 | 0.02 | 0.25 |
EPS (Diluted) | -0.39 | -0.39 | -0.27 | -1.35 | 0.02 | 0.25 |
EPS Growth | - | - | - | - | -92.00% | -7.41% |
Free Cash Flow | -150.95 | -67.68 | -183.37 | -205.6 | -428.1 | -305.21 |
Free Cash Flow Per Share | -0.17 | -0.07 | -0.20 | -0.22 | -0.49 | -0.33 |
Dividend Per Share | - | - | - | - | 0.005 | 0.026 |
Dividend Growth | - | - | - | - | -80.77% | - |
Gross Margin | 2.76% | 2.38% | 9.07% | -22.88% | 43.71% | 58.01% |
Operating Margin | -26.96% | -26.98% | -17.34% | -81.17% | 4.62% | 10.92% |
Profit Margin | -40.78% | -40.90% | -24.20% | -87.93% | 0.75% | 7.87% |
Free Cash Flow Margin | -17.30% | -7.73% | -17.79% | -14.58% | -18.32% | -10.28% |
EBITDA | -169.22 | -168.81 | -106.43 | -1,071 | 164.93 | 379.86 |
EBITDA Margin | -19.39% | -19.29% | -10.32% | -75.90% | 7.06% | 12.80% |
D&A For EBITDA | 65.99 | 67.26 | 72.35 | 74.39 | 56.94 | 55.8 |
EBIT | -235.21 | -236.07 | -178.78 | -1,145 | 107.99 | 324.06 |
EBIT Margin | -26.96% | -26.98% | -17.34% | -81.17% | 4.62% | 10.92% |
Effective Tax Rate | - | - | - | - | 43.94% | 11.19% |
Revenue as Reported | 872.53 | 875.13 | 1,031 | 1,410 | 2,336 | 2,968 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.